Press releases

^{Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.}

YearType

2025

30 okt 2025, 07:00 | Regulatory

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

· Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
· First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy.

29 okt 2025, 18:00

Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

10 okt 2025, 10:00

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

Results presented today at ESGCT 2025

8 okt 2025, 16:00

Hansa Biopharma to host Q3 2025 interim results conference call

7 okt 2025, 17:00

Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025

2 okt 2025, 08:30 | Regulatory

Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm

2 okt 2025, 00:15 | Regulatory